~~<i id='6ECC413341'><strike id='6ECC413341'><tt id='6ECC413341'><pre id='6ECC413341'></pre></tt></strike></i>~~

Home» Wikipedia» focus

focus

author：explore 2025-10-04 10:46:00 Page View：88862

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn
Next article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

explore

ChatGPT in medicine: STAT answers readers' burning questions

MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

Maui's cultural, historic landmarks damaged in the devastating wildfires

4:12AsatelliteimageshowsanoverviewofBanyancourtinLahaina,Maui,Aug.9,2023.MaxarTechnologiesviaAFP/Get

How one medical school became remarkably diverse

ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

FDA panel issues narrow recommendation for Covid vaccine booster doses

ROBYNBECK/AFPviaGettyImagesForanarchivedversionoflivecoverageofthehearingoftheFDA’sadvisorypanel,cli